Literature DB >> 17888957

Lung transplantation for idiopathic pulmonary fibrosis.

David P Mason1, Mariano E Brizzio, Joan M Alster, Ann M McNeill, Sudish C Murthy, Marie M Budev, Atul C Mehta, Omar A Minai, Gösta B Pettersson, Eugene H Blackstone.   

Abstract

BACKGROUND: Outcomes of lung transplantation for idiopathic pulmonary fibrosis (IPF) are thought to be worse than those for other indications, although the reasons are unknown. In addition, the choice of single versus double lung transplantation is unclear. To guide decision-making, we (1) compared survival of patients receiving transplantation for IPF with survival of patients receiving transplantation for non-IPF diagnoses, (2) identified risk factors for mortality after transplantation for IPF, and (3) ascertained whether double lung transplantation for IPF confers a survival advantage.
METHODS: From February 1990 to November 2005, 469 patients underwent lung transplantation, 82 for IPF. Multiphase hazard modeling was used to identify risk factors, and propensity matching was used to compare survival of IPF and non-IPF patients and to assess the effect of single versus double lung transplantation.
RESULTS: Survival estimates after transplantation for IPF were 95%, 73%, 56%, and 44% at 30 days and 1, 3, and 5 years, somewhat worse than for matched non-IPF patients (p = 0.03). Risk factors for mortality were earlier date of transplantation (p = 0.07), single lung transplantation (p = 0.03), and higher wedge pressure (p = 0.003). Survival for double versus single lung transplantation was 81% versus 67% at 1 year and 55% versus 34% at 5 years; however, among matched non-IPF patients, corresponding survivals were 88% versus 71% at 1 year and 72% versus 48% at 5 years (p = 0.3).
CONCLUSIONS: Survival after lung transplantation for IPF is worse than after other indications for transplantation when multiple clinical variables are accounted for. Survival may be improved by double lung transplant.

Entities:  

Mesh:

Year:  2007        PMID: 17888957     DOI: 10.1016/j.athoracsur.2007.04.096

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  20 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

Review 3.  Bilateral versus single lung transplantation: are two lungs better than one?

Authors:  Melanie P Subramanian; Bryan F Meyers
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

4.  Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: Case Report and systematic literature review.

Authors:  Neelam Giri; Rees Lee; Albert Faro; Charles B Huddleston; Frances V White; Blanche P Alter; Sharon A Savage
Journal:  BMC Blood Disord       Date:  2011-06-15

5.  Bilateral lung transplantation offers better long-term survival, compared with single-lung transplantation, for younger patients with idiopathic pulmonary fibrosis.

Authors:  Seth D Force; Pat Kilgo; David C Neujahr; Andres Pelaez; Allan Pickens; Felix G Fernandez; Daniel L Miller; Clint Lawrence
Journal:  Ann Thorac Surg       Date:  2011-01       Impact factor: 4.330

6.  Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation.

Authors:  Aric L Gregson; Xiaoyan Wang; S Sam Weigt; Vyacheslav Palchevskiy; Joseph P Lynch; David J Ross; Bernard M Kubak; Rajan Saggar; Michael C Fishbein; Abbas Ardehali; Gang Li; Robert Elashoff; John A Belperio
Journal:  Am J Respir Crit Care Med       Date:  2013-01-17       Impact factor: 21.405

Review 7.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

8.  CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis.

Authors:  Syed R Gilani; Louis J Vuga; Kathleen O Lindell; Kevin F Gibson; Jianmin Xue; Naftali Kaminski; Vincent G Valentine; Emily K Lindsay; M Patricia George; Chad Steele; Steven R Duncan
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

Review 9.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415

10.  Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation.

Authors:  Liesbeth ten Klooster; George D Nossent; Johanna M Kwakkel-van Erp; Diana A van Kessel; Erik J Oudijk; Ed A van de Graaf; Bart Luijk; Rogier A Hoek; Bernt van den Blink; Peter Th van Hal; Erik A Verschuuren; Wim van der Bij; Coline H van Moorsel; Jan C Grutters
Journal:  Lung       Date:  2015-09-24       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.